URGN — UroGen Pharma Ltd.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1668243 ·
Last close
$32.81
Market Cap
$1.60B
52W High
$33.40
52W Low
$16.50
ADV30
832,856
Next earnings
2026-08-06
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 50,959,000 | 46,820,000 | -20,263,000 | -23,574,000 | 253,690,000 | 109,968,000 | 377,943,000 |
| Dec 2025 | 37,837,000 | 34,548,000 | -19,115,000 | -26,364,000 | 200,455,000 | 110,745,000 | 305,929,000 |
| Sep 2025 | 27,482,000 | 24,204,000 | -27,386,000 | -33,347,000 | 185,046,000 | 90,039,000 | 300,454,000 |
| Jun 2025 | 24,215,000 | 20,665,000 | -41,448,000 | -49,940,000 | 208,717,000 | 92,904,000 | 302,093,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-162,444,000
Investing CF
$61,558,000
Financing CF
$39,918,000
CapEx
$-289,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.20
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-959,716,000
Inventory
$16,464,000
Receivables
$33,082,000
ST Investments
$9,711,000
EBIT TTM
$-138,071,000
Pretax Income TTM
$-153,416,000
Interest Exp TTM
$15,345,000
Analysts
8
Yahoo Snapshot (yfinance, live)
Total Revenue
$140,492,992
EBITDA
$-107,902,000
Free Cash Flow
$-109,282,248
Enterprise Value
$1,613,477,376
Total Cash
$140,274,000
Total Debt
$197,092,992
Shares Out
48,721,701
Trailing EPS
$-2.74
Book Value
$-2.55
ROE
—
ROA
-27.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 109,788,000 | -124,863,000 | -153,494,000 | 200,455,000 | 305,929,000 | — | -162,444,000 |
| Dec 2024 | 90,398,000 | -96,782,000 | -126,874,000 | 285,711,000 | 294,514,000 | — | -96,766,000 |
| Dec 2023 | 82,713,000 | -65,536,000 | -102,244,000 | 178,311,000 | 243,523,000 | — | -76,376,000 |
| Dec 2022 | 64,357,000 | -79,041,000 | -109,783,000 | 135,619,000 | 224,980,000 | — | -87,559,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$1.23
Max Pain — expiry 2027-01-15
max pain strike: $25.00 · spot: $32.81 · call oi: 56 · put oi: 1,045Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AAPG | ASCENTAGE PHARMA GROUP INTERNATIONAL | $1.60B | $17.09 | — |
| CMPS | COMPASS Pathways plc | $1.61B | $11.94 | — |
| SEPN | Septerna, Inc. | $1.61B | $35.80 | — |
| PVLA | PALVELLA THERAPEUTICS, INC. | $1.62B | $112.63 | — |
| CAPR | CAPRICOR THERAPEUTICS, INC. | $1.62B | $27.95 | — |
News headlines (Yahoo Finance, 1h cache)
Is UroGen Pharma a Stock to Sell After Its Chief Medical Officer Unloaded 5,222 Shares?
2026-06-14 15:34 · Yahoo
Will UroGen’s Jelmyto Generic Deal with Teva Redefine UroGen Pharma's (URGN) Narrative?
2026-06-08 10:06 · Yahoo
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-06-05 12:00 · Yahoo
UroGen Announces Agreement Resolving Patent Litigation Relating to JELMYTO® (mitomycin) for pyelocalyceal solution
2026-06-02 12:00 · Yahoo
UroGen Pharma to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
2026-06-01 20:10 · Yahoo
What to Know About This Fund's $6.6 Million UroGen Sale After a 600% Stock Surge
2026-05-23 22:40 · Yahoo
Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock Rally
2026-05-23 22:33 · Yahoo
How UGN-103’s Strong Phase 3 UTOPIA Data Could Shape UroGen Pharma (URGN) Investors
2026-05-21 21:18 · Yahoo
Sector Update: Healthcare Stocks Gain Late Afternoon
2026-05-19 19:55 · Yahoo
UroGen Pharma Investor Event Reinforced Zusduri Commercial Thesis, Oppenheimer Says
2026-05-19 14:55 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.